The Experts below are selected from a list of 3507 Experts worldwide ranked by ideXlab platform

Michael Ramharter - One of the best experts on this subject based on the ideXlab platform.

  • a systematic review of the clinical presentation treatment and relapse characteristics of human Plasmodium Ovale Malaria
    Malaria Journal, 2017
    Co-Authors: Mirjam Groger, Michael Ramharter, Hannah S Fischer, Luzia Veletzky, Albert Lalremruata
    Abstract:

    Despite increased efforts to control and ultimately eradicate human Malaria, Plasmodium Ovale Malaria is for the most part outside the focus of research or public health programmes. Importantly, the understanding of P. Ovale—nowadays regarded as the two distinct species P. Ovale wallikeri and P. Ovale curtisi—largely stems from case reports and case series lacking study designs providing high quality evidence. Consecutively, there is a lack of systematic evaluation of the clinical presentation, appropriate treatment and relapse characteristics of P. Ovale Malaria. The aim of this systematic review is to provide a systematic appraisal of the current evidence for severe manifestations, relapse characteristics and treatment options for human P. Ovale Malaria. This systematic review was performed according to the PRISMA guidelines and registered in the international prospective register for systematic reviews (PROSPERO 2016:CRD42016039214). P. Ovale mono-infection was a strict inclusion criterion. Of 3454 articles identified by the literature search, 33 articles published between 1922 and 2015 met the inclusion criteria. These articles did not include randomized controlled trials. Five prospective uncontrolled clinical trials were performed on a total of 58 participants. P. Ovale was sensitive to all tested drugs within the follow-up periods and on interpretable in vitro assays. Since its first description in 1922, only 18 relapsing cases of P. Ovale with a total of 28 relapse events were identified in the scientific literature. There was however no molecular evidence for a causal relationship between dormant liver stages and subsequent relapses. A total of 22 severe cases of P. Ovale Malaria were published out of which five were fatal. Additionally, two cases of congenital P. Ovale Malaria were reported. Current knowledge of P. Ovale Malaria is based on small trials with minor impact, case reports and clinical observations. This systematic review highlights that P. Ovale is capable of causing severe disease, severe congenital Malaria and may even lead to death. Evidence for relapses in patients with P. Ovale Malaria adds up to only a handful of cases. Nearly 100 years after P. Ovale’s first description by Stephens the evidence for the clinical characteristics, relapse potential and optimal treatments for P. Ovale Malaria is still scarce.

  • Case report: spontaneous rupture of spleen in patient with Plasmodium Ovale Malaria
    Wiener klinische Wochenschrift, 2016
    Co-Authors: Raphael Lemmerer, Peter Starzengruber, Michael Ramharter, Manuel Unger, Matthias Voßen, Christina Forstner, Ahmad Jalili, Johannes Werzowa, Stefan Winkler, Florian Thalhammer
    Abstract:

    Malaria may lead to spontaneous splenic rupture as a rare but potentially lethal complication. Most frequently, this has been reported in patients infected with Plasmodium falciparum and Plasmodium vivax , while other parasitic agents are less likely to be the cause. We report a 29-year-old British Caucasian, who after returning from a business trip in Democratic Republic Congo was diagnosed with tertian Malaria caused by Plasmodium Ovale . During his in-patient stay, the patient suffered a splenic rupture requiring immediate surgical intervention and splenectomy. Following this surgical intervention, there was an uneventful recovery, and the patient was discharged in a good general condition.

Raúl De Pablo-sánchez - One of the best experts on this subject based on the ideXlab platform.

E Nicastri - One of the best experts on this subject based on the ideXlab platform.

  • severe Plasmodium Ovale Malaria complicated by acute respiratory distress syndrome in a young caucasian man
    Malaria Journal, 2018
    Co-Authors: Alessandra Dabramo, Saba Gebremeskel Tekle, Marco Iannetta, Laura Scorzolini, Alessandra Oliva, Maria Grazia Paglia, Angela Corpolongo, E Nicastri
    Abstract:

    Although Plasmodium Ovale is considered the cause of only mild Malaria, a case of severe Malaria due to P. Ovale with acute respiratory distress syndrome is reported. A 37-year old Caucasian man returning home from Angola was admitted for Ovale Malaria to the National Institute for Infectious Diseases Lazzaro Spallanzani in Rome, Italy. Two days after initiation of oral chloroquine treatment, an acute respiratory distress syndrome was diagnosed through chest X-ray and chest CT scan with intravenous contrast. Intravenous artesunate and oral doxycycline were started and he made a full recovery. Ovale Malaria is usually considered a tropical infectious disease associated with low morbidity and mortality. However, severe disease and death have occasionally been reported. In this case clinical failure of oral chloroquine treatment with clinical progression towards acute respiratory distress syndrome is described.

Helena H Askling - One of the best experts on this subject based on the ideXlab platform.

  • relapse of Plasmodium vivax and Plasmodium Ovale Malaria with and without primaquine treatment in a non endemic area
    Clinical Infectious Diseases, 2021
    Co-Authors: Andreas Wangdahl, Klara Sonden, Katja Wyss, Christine Stenstrom, David Bjorklund, Jessica Zhang, Helena H Askling
    Abstract:

    BACKGROUND The effect of primaquine in preventing P. vivax relapses from dormant stages is well established. For P. Ovale, the relapse characteristics and the use primaquine is not as well studied. We set to evaluate the relapsing properties of these two species, in relation to primaquine use among imported Malaria cases in a non-endemic setting. METHODS We performed a nationwide retrospective study of Malaria diagnosed in Sweden 1995-2019, by reviewing medical records of 3254 cases. All episodes of P. vivax (n=972) and P. Ovale (n=251) were selected for analysis. RESULTS First time relapses were reported in 80/857 (9.3%) P. vivax and 9/220 (4.1%) P. Ovale episodes, respectively (p<0.01). Without primaquine, the risk for relapse was higher in P. vivax, 20/60 (33.3%), compared to 3/30 (10.0%) in P. Ovale (HR 3.5, 95% CI 1.0-12.0). In P. vivax, patients prescribed primaquine had a reduced risk of relapse compared to episodes without relapse preventing treatment, 7.1% vs 33.3%, (HR 0.2, 95%CI 0.1-0.3). In P. Ovale, the effect of primaquine on the risk of relapse did not reach statistical significance, with relapses seen in 2.8% of the episodes compared to 10.0% in patients not receiving relapse preventing treatment (HR 0.3, 95% CI 0.1-1.1). CONCLUSION The risk of relapse was considerably lower in P. Ovale than in P. vivax infections indicating different relapsing features between the two species. Primaquine was effective in preventing P. vivax relapse. In P. Ovale, relapse episodes were few and the supportive evidence for primaquine remains limited.

Gerardo Rojo-marcos - One of the best experts on this subject based on the ideXlab platform.